Search

Your search keyword '"OVERALL survival"' showing total 2 results
2 results on '"OVERALL survival"'

1. From the Co-Editor in Chief: BCG-unresponsive NMIBC: Advancements are moving the needle.

Author

Cookson, Michael S.

Subjects
*NON-muscle invasive bladder cancer, *GENE therapy, *UROLOGY, *BCG vaccines, *IMMUNOTHERAPY, *ANTINEOPLASTIC agents, *DISEASE management, *TREATMENT effectiveness, *SEVERITY of illness index, *IMMUNE checkpoint inhibitors, *OVERALL survival, BLADDER tumors
Abstract

The article highlights advancements in the treatment of Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). These include nadofaragene firadenovec intravesical gene therapy, pembrolizumab systemic therapy, TAR-200 drug intravesical delivery system using gemcitabine and gemcitabine plus a PD-L1 inhibitor, combination chemotherapy with gemcitabine and docetaxel, and QUILT-3.032 study on the synergy between immune checkpoint inhibitors and targeted therapies.

Published
2024

2. Prostate cancer treatment deintensification: When less is more.

Author

COOKSON, MICHAEL S.

Subjects
*PROSTATE tumors treatment, *DISEASE progression, *ANTIANDROGENS, *INDIVIDUALIZED medicine, *TREATMENT effectiveness, *RISK assessment, *ADVERSE health care events, *DISEASE management, *PROSTATE tumors, *OVERALL survival
Abstract

In the article, the author discusses updates in the treatment of patients with advanced and metastatic prostate cancer, particularly the clinical trials showing the efficacy of treatment deintensification in the proper clinical context. Other topics include the potential benefits of deintensification like reduction of treatment-related adverse events (TRAE) and the various deintensification methods like radiation therapy with omission of androgen deprivation therapy (ADT).

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results